AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 32 min read$VRTX

Vertex: Q3 Earnings Snapshot

Vertex Pharmaceuticals (VRTX) reported Q3 profit of $653.6M, or $2.56 per share, missing estimates of $4.92 per share. Revenue was $3.44B, exceeding forecasts of $3.4B. The company expects full-year revenue between $13.15B and $13.25B.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 4:37 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 4:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Vertex: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$VRTXBullishMed
01

Why it matters

The earnings miss on EPS may trigger short-term selling pressure, but the revenue beat and full-year guidance could provide support.

02

Market read

First-report earnings data for a large-cap biotech; relevant for healthcare investors and short-term traders.

03

What to watch

Strong full-year revenue guidance may offset short-term EPS disappointment.

Relevance 8/10Novelty 8/10Timing: after market close

Background

Vertex Pharmaceuticals released its third-quarter earnings, providing fresh financial metrics and guidance.

Company-level read

Ticker impact

$VRTXBullishMedium confidence
Context

Vertex reported Q3 profit of $653.6M, EPS $4.76, missing consensus of $4.92 while revenue $3.44B beat estimates.

Expected impact

likely pressure as investors price in the EPS miss

Evidence & confidence

The miss on earnings per share is a key metric for biotech investors and often triggers short-term downside.

Market effects

Sector

Biotech sector may see modest pullback as earnings miss highlights valuation pressure.

Regional

U.S. markets may see slight dip in healthcare indices.

Global

Limited to investors tracking large-cap biotech earnings.

Counterpoint

What could challenge this read

Revenue beat could support a rebound if guidance remains strong.

Key entities

  • Company
    Vertex Pharmaceuticals Inc.

    Biotech firm reporting Q3 results.

Read at source← All news

StoryVertex raises 2026 revenue outlook after strong Q3 results and Crinetics acquisition

Also covered by

5 outlets

Related articles

NOV 3
$VRTXHighAI 8/10

Vertex Pharmaceuticals Q3 Earnings Call Highlights

Vertex Pharmaceuticals raised its full-year revenue guidance to $13.15B-$13.25B, citing contributions from Crinetics. Q3 saw $2B in revenue from ALYFTREK, CASGEVY, and JOURNAVX, with ALYFTREK leading at $706M. Vertex also reported progress in renal and cystic fibrosis pipelines, including regulatory submissions for ALYFTREK in younger children and early data for VX-828. The company ended Q3 with $9.8B in cash and investments.

finance.yahoo.com3 min
NOV 2
$VRTXMedAI 9/10

Why is Vertex Pharmaceuticals stock climbing today?

Vertex Pharmaceuticals (VRTX) stock rose 0.7% after-hours after reporting Q3 2026 results. Revenue of $3.44B beat estimates, and the company raised its full-year revenue guidance to $13.15B-$13.25B. CEO Kewalramani highlighted strong revenue growth and R&D advancements. Key products CASGEVY and JOURNAVX showed significant growth, and the company completed its acquisition of Crinetics Pharmaceuticals.

investing.com5 min
NOV 2
$VRTXMedAI 8/10

Vertex Pharma meets Q3 estimates, raises revenue guidance

Vertex Pharmaceuticals (VRTX) reported Q3 earnings of $4.76 per share, meeting estimates, and revenue of $3.44B, slightly above expectations. The company raised its 2026 revenue guidance to $13.15B-$13.25B. U.S. revenue rose 10% to $2.17B, while international revenue increased 16% to $1.27B. CASGEVY and JOURNAVX showed significant growth. Vertex completed its acquisition of Crinetics Pharmaceuticals for $9.0B.

investing.com4 min
NOV 2
$VRTXMedAI 8/10

Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction

Vertex Pharmaceuticals reported Q3 revenue of $3.44B, up 12%, driven by its newer CF drug Alyftrek. Adjusted profit was flat due to spending on new launches and the Crinetics deal. Shares rose 1.5% in after-hours trading. Non-CF revenue also increased to $168M. The company expects continued investment in new drugs to impact near-term profitability.

fool.com6 min